INTRODUCTION
============

Methylation of cytosine residues is a major epigenetic mechanism in mammalian cells, and the only known endogenous covalent DNA modification ([@B1]). Mammalian DNA methylation occurs on both DNA strands at the 5′ cytosine in a CpG pair. CpG dinucleotides are the least frequent nucleotide pairs and they are distributed in clusters, or CpG islands, throughout the genome. Using the classical CpG island definition ([@B2]), there are approximately 29 000 CpG islands (each greater than 200 bp long, containing \>50% GC and with an observed/expected CpG ratio of \>0.6) representing ∼ 1% of the human genome. Overall 60--90% of genomic CpGs are thought to be methylated ([@B3; @B4; @B5]), and this is largely determined by their location within the genome. CpG pairs outside of CpG islands are usually methylated, those within such islands have long been thought to be protected against methylation. More recent studies have shown that CpG islands, in particular of tumor specific genes (e.g. *SPHK*1) can also be methylated ([@B6]).

DNA methylation plays an important role in gene regulation and differential gene silencing. In all organisms investigated, methylation patterns are maintained during mitosis. During meiosis parental genomes are demethylated and individual foetal methylation patterns are established during embryogenesis. Evidence from monozygotic twins suggests that the foetal environment tightly regulates methylation patterns: differences between monozygotic twins only develop after birth, increasing with age when global methylation levels fall ([@B7]). X-chromosome inactivation, and gene imprinting, both methylation dependent, occur at this early stage of development ([@B8]). DNA methylation studies have, largely, been limited to less than 100 genes known to be imprinted ([@B9]). However, DNA methylation is not limited to imprinted regions. More recently it has been suggested that DNA methylation outside these imprinted regions may underlie long-term programming effects, especially perinatally ([@B10],[@B11]).

Methylation patterns established during embryogenesis vary significantly between tissues. Although a role for DNA methylation in tissue-specific gene expression was suggested already in 1975 ([@B12],[@B13]), it was not until recently that this has been experimentally confirmed, by Song *et al*. ([@B14]) who identified some 150 such regions. *In vivo*, embryonic stem cells differentiating for instance to neuronal precursor cells and astrocytes undergo gradual tissue-specific methylation, particularly in CpG islands. *In vitro*, these cells become hypermethylated after extended proliferation ([@B15],[@B16]). Also, astroglial differentiation is associated with demethylation of JAK-STAT pathway genes ([@B17],[@B18]).

CpG islands frequently contain transcription start sites (TSS) and 5′ promoter regions of housekeeping genes as well as tissue-specific genes. Although it is now recognised that methylation also occurs in CpG islands, the role of methylation of promoter elements in CpG islands, especially those associated with non-imprinted or non-oncogenes, has received little attention. Detailed examination of mRNA transcripts has recently shown that the vast majority of human genes show significant diversity in their 5′ region ([@B19]). Currently, it is estimated that more than 50% of genes possess alternative 5′ TSS each with its own promoter ([@B20]). On average genes have 3.1 promoters, but they can have as many as 10 alternative promoters and TSS ([@B21]). Evolutionarily conserved alternative promoters, identified by inter-species sequence homology, were predominantly (78%) located within CpG islands upstream of housekeeping or ubiquitously expressed genes. This raises the question as to the relations between CpG methylation and transcript variability within CpG islands and their roles, especially in the context of ubiquitously expressed, but tightly controlled genes. Although differential methylation of these sensitive regions may play a critical role in the regulation of many genes, there are very few studies where methylation patterns have been analysed within a single complex CpG island containing multiple first exons and alternative promoters.

The type II glucocorticoid receptor (*GR*, OMIM +138040; *NR3C1*) is an ubiquitously transcribed nuclear hormone receptor with an unusually complex promoter structure. *GR* transcription is controlled through nine promoters each associated with an alternative TSS, seven of which are found in an upstream CpG island ([@B22],[@B23]). This transcript variability does not alter the protein produced since the ATG translation start codon is in exon 2. We and others have hypothesised that TSS usage, resulting in differential *GR* tissue expression profiles depends on short, immediately upstream proximal promoter regions within the CpG island. The *GR* and glucocorticoids (GC) are involved in many physiological processes, and play a major role in the hypothalamus-pituitary-adrenal (HPA) response to stress. This is a highly regulated system, controlled by GC feedback to the hippocampus and hypothalamus. This system is also known to be susceptible to differential methylation ([@B24]). Variability in HPA axis feedback sensitivity in the rat has been explained by changes in methylation of the transcription inducing nerve growth factor inducible-A (NGFI-A, also called KROX, EGR1, or ZIF286) binding site in the promoter of exon 1~7~. As most other *GR* promoters, 1~7~ is located in an upstream CpG island ([@B25],[@B26]). We investigate here the positions and levels of CpG methylation of *GR* alternative exons and their promoters in order to understand the role and pattern of methylation in the CpG island upstream of a gene containing a complex promoter structure.

For this purpose, we have analysed differential methylation of alternative *GR* promoters in peripheral blood mononuclear cells (PBMC) by bisulphate sequencing. We have previously shown that PBMC express almost all alternative first exons (e.g. 1B, C, D, E, F and H) ([@B22]). We also examine the evolutionarily conserved TFBS pattern using an improved *in silico* phylogenetic footprinting technique. The majority of CpG positions in conserved TFBS were methylatable, and methylation patterns were highly individualised among donors. The heterogeneity of methylation patterns observed in our study may reflect differences in early life environment and events.

MATERIALS AND METHODS
=====================

Genomic alignments
------------------

Genomic DNA of the human chromosome 5 (July 2004, UCSC) was aligned with rat (AJ271870, NCBI), mouse (NCBIM35:18:39863309:39869358:1, Ensembl), chimpanzee (CHIMP1A:5:149403812:149409861:1, Ensembl) and cow (ChrUn.313:334239:339538:1, Ensembl) sequences upstream of the *GR* exon 2 using Vector NTi 10.1.1 (Invitrogen, Paisley, UK) as previously reported ([@B27]).

*In silico* phylogenetic footprinting (*IS*PF)
----------------------------------------------

Genomic sequences predicted by homology to contain the promoter regions of exons 1D, 1E, 1F and 1H were screened for potential transcription factor binding sites (TFBS) using the MATCH algorithm ([@B28]) from TRANSFAC® Professional (version 10.1). The cut-off values for the core and matrix similarity scores of acceptable binding site predictions were set to 0.98 and 0.95, respectively (1.0 = exact match). TRANSFAC-predicted binding sites were transposed onto the multi-species genomic alignment to identify coincident sites. The results were expressed as the number of species where the first nucleotide of identical transcription factor matrices coincide for each position within the alignment.

Subjects
--------

Twenty-six healthy subjects (22 female and 4 male, age range 35--67 years, mean 51 ± 8 years) were recruited by the Department of Psychobiology, University of Trier, Germany. The study protocol was approved by the ethics committee of the Rheinland-Pfalz State Medical Association and written informed consent was given by all participating subjects.

Exclusion criteria were based on medical history and physical examination. They were designed to minimize the influence of disease and drugs, and included: steroid use (except for oral contraception or hormone replacement therapy due to menopause); infections during the preceding 2 weeks; dietary weight loss of 5 kg or more within 6 weeks before study entry; pregnancy or breastfeeding; alcohol or drug dependence; severe allergies; hematological, endocrine, cardiovascular, pulmonary, gastrointestinal, renal, hepatic, autoimmune or psychiatric disorders. The subjects were also evaluated with the German version of the Structured Clinical Interview for DSM-IV ([@B29]) to exclude major depression disorder. From each subject, one blood sample was collected between 08:30 and 09:00 hours under basal conditions.

Isolation of genomic DNA from PBMCs
-----------------------------------

Human PBMCs were purified from heparinised blood by Ficoll-Isopaque (Amersham, UK) using Leucosep tubes (Greiner Bio-one, Germany). After three washes in HBSS (Biowhittaker, Verviers, Belgium), cells were resuspended in RPMI, 10% FBS, 10% DMSO and stored in liquid nitrogen until further analysis. For DNA isolation, cells were washed and resuspended in 2 ml of PBS. DNA was purified using the QIAamp® DNA Blood Midi kit (Qiagen, Venlo, The Netherlands) and stored at --20°C.

Bisulphite treatment
--------------------

The EpiTect Bisulfite kit (Qiagen) converts unmethylated cytosine residues to uracil, whereas methylated cytosines remain unmodified. According to the manufacturers' protocol, the first two steps of bisulphite treatment were performed on 400 ng of genomic DNA. The thermal cycler (Mastercycler gradient, Eppendorf, Hamburg, Germany) program comprised several incubation steps for DNA denaturation, sulphonation of unmethylated cytosine, and deamination of cytosine sulphonate to uracil sulphonate. Cycling conditions were as follows: first denaturation for 5 min at 99°C, first incubation for 25 min at 60°C, second denaturation for 5 min at 99°C, second incubation for 85 min at 60°C, third denaturation for 5 min at 99°C, third incubation for 175 min at 60°C and hold at 20°C. Alkaline uracil desulphonation and sample purification were performed using a spin column. Modified DNA was eluted and stored at --20°C until analysis.

PCRs and methylation quantification
-----------------------------------

The bisulphite-modified DNA was used to amplify promoters of exons 1D, 1E, 1F and 1H with the primers and under the conditions shown in [Table 1](#T1){ref-type="table"}. Table 1.PCR primers and reaction conditions for bisulphite sequencingPrimer sequence[^a^](#TF1){ref-type="table-fn"}Amplified region[^b^](#TF2){ref-type="table-fn"}Length (bp)*T*~m~ (°C)[^c^](#TF3){ref-type="table-fn"}\[MgCl~2~\] (mM)\[Primers\] (μM)Promoter 1DD~A~Fwd: 5′-ATATTAGATAATGTATAGGGAATYGTTTAT-3′ Rev: 5′-CCRCCRCCATCTTAATAAAATACAATATC-3′-4724 to -45841404920.5D~B~Fwd: 5′-TGTTAAGATGGTGGTYGYGGGGAYGG-3′ Rev: 5′-AACTACCRCAACTCCACCTAATCC-3′-4644 to -44382065920.1D~BII~Fwd: 5′-GGTYGYGGGGAYGGGTTGGYGATATTGT-3′ Rev: 5′-CCTACTCRAACRCTCRACCACAACC-3′-4632 to -44601725910.1Promoter 1EEFwd: 5′-GGGAGTTGAAYGTTGGTATTTTAAAGTTG-3′ Rev: 5′-CTCRAAAAAAATTACACRCCAAATAC-3′-4129 to -37813485420.1E~II~Fwd: 5′-GTATTTTGTTTTATTTGTAGGGGTAGG-3′ Rev: 5′-TACAAAACCTCCAACRAACTAAATT-3′-4097 to -38042935510.1Promoter 1FF~A~Fwd: 5′-TGAAGATTYGGTYGTTTAGATGAT-3′ Rev: 5′-ACCRAATTACRTAAAATATATCACTTCRAA-3′-3605 to -33782275021F~AII~Fwd: 5′-TGGTGGGGGATTTGTYGGTAYGYGA-3′ Rev: 5′-TCACTTCRAAAAAAACTACRAAATTACA-3′-3577 to -33981795220.5F~B~Fwd: 5′-GGTYGAGAYGTTGYGGTATYGTTTTYGTG-3′ Rev: 5′-CCTTAACRACAAACRCCRCCAATAC-3′-3452 to -32681845041F~BII~Fwd: 5′-GTTGYGGTATYGTTTTYGTGTAATTT-3′ Rev: 5′-ACRAATAACAACRAACRAACCACAA-3′-3443 to -32971465320.1F~C~Fwd: 5′-TTGTGGTTYGTTYGTTGTTATTYGTAGG-3′ Rev: 5′-CACCRAATTTCTCCAATTTCTTTTCTC-3′-3321 to -31771445421F~CII~Fwd: 5′-TTGTGGTTYGTTYGTTGTTATTYGTAGG-3′ Rev: 5′-CAATTTCTTTTCTCRCTACCTCCTTCC-3′-3321 to -31901315220.5Promoter 1HH~A~Fwd: 5′-TTYGGTTGYGGYGGGAATTGYGGAYGGTG-3′ Rev: 5′-AAACTAATAAAAATTTATAAACTCC-3′-2422 to -22581645620.5H~AII~Fwd: 5′-GGTGGYGGGYGAGYGGTTTTTTTGTTAGAG-3′ Rev: 5′-ACTCCCRCRACRACCCCCRAATTATCTC-3′-2397 to -22761215810.1H~B~Fwd: 5′-GGGYGYGTTYGTTTTTTYGAGGTGTYGTTG-3′ Rev: 5′-CTCCCCCTCRACCCRACCAAA-3′-2341 to -21352065510.1H~BII~Fwd: 5′-GAGATAATTYGGGGGTYGTYGYGGGAG-3′ Rev: 5′-ACCCRACCAAAAAACRCCTAC-3′-2305 to -21451605610.1H~C~Fwd: 5′-TTTYGTAGGYGTTTTTTGGTYGGGTYGAG-3′ Rev: 5′-AATTCAAACRCRACTTAACRTTCACCACRAA-3′-2169 to -19672025121H~CII~Fwd: 5′-TTTYGTAGGYGTTTTTTGGTYGGGTYGAG-3′ Rev: 5′-CCAAAATTCCCRCRAAAAATAAAAAACTC-3′-2169 to -20551145530.1H~D~Fwd: 5′-GGTYGTTYGATATTYGTTTTYGTGGTG-3′ Rev: 5′-CCCRCTTATACACCCTCAC-3′-2015 to -18441715210.1H~DII~Fwd: 5′-GTGGTGAAYGTTAAGTYGYGTTTG-3′ Rev: 5′-CCRCACRCCCTCCTCAAACCA-3′-1994 to -18681265320.1H~DIII~Fwd: 5′-GGTYGTTYGATATTYGTTTTYGTGGTG-3′ Rev: 5′-CCRCACRCCCTCCTCAAACCA-3′-2015 to -18681475211[^1][^2][^3]

PCR was performed using 20 mM Tris--HCl (pH 8.4), 50 mM KCl, 200 mM deoxynucleoside triphosphates, 1× SyBR Green and 2.5 U Platinum *Taq* DNA polymerase (Invitrogen, Merelbeke, Belgium) on an Opticon 2 thermal cycler (MJ Research). Cycling conditions were as follows: 95°C for 2 min, 40 cycles, at 95°C for 20 s, annealing temperature ([Table 1](#T1){ref-type="table"}) for 20 s and 72°C for 25 s. Products of D~B~, E, F~A~, F~B~, F~C~, H~A~, H~B~, H~C~ and H~D~ PCRs were used as a template (20-fold dilution) for nested amplifications using the primers and conditions in [Table 1](#T1){ref-type="table"}.

Methylation analysis of promoter 1D, 1E, 1H and the 215 first nucleotides of promoter 1F were determined manually. Such peak intensity-based quantification has previously been validated for methylation quantification ([@B30]). The nested PCR products (D~BII~, E~II~, F~AII~, F~BII~, F~CII~, H~AII~, H~BII~, H~CII~, H~DII~ and H~DIII~) and the D~A~ PCR products were directly sequenced after spin column purification (Genomed, Löhne, Germany).

Methylation analysis of the promoter 1F proximal area (F~CII~) was determined by multiple trace single population quantification. The F~CII~ semi-nested PCR products were cloned into the pCR4-TOPO vector (Invitrogen) and used to transform Top10 electrocompetent *E. coli* (Invitrogen). For each subject, 10--12 clones were sequenced using 100 nM M13 primers and the BigDye 3.1 Terminator cycle sequencing reagent (Applied Biosystems, Nieuwerkerk, The Netherlands) on the ABI 3130 sequencer (Applied Biosystems). Methylation percentage at each position is calculated from the ratio of the numbers of methylated to unmethylated colonies.

RESULTS
=======

Identification of known TFBS by *IS*PF
--------------------------------------

*IS*PF was performed over all genomic regions containing *GR* promoters with experimentally identified transcription factors ([Table 2](#T2){ref-type="table"}). The genomic DNA of the complete CpG islands of the five species, the mouse, rat, cow, chimpanzee and man were aligned. The coincidental predictions of the TRANSFAC analyses and genomic alignment identified the evolutionarily conserved transcription factors. Transcription factors have been experimentally identified for promoters 1B ([@B31]), 1~7~ \[1F homologue, ([@B25])\] and probably 1D ([@B32]). Table 2.Regulatory element of the GR promoter region can be predicted by *in silico* phylogenetic footprintingPromoterTranscription factorIdentification technique*IS*PFPrediction1BSP1 (x3)RG, FP, E5,4,5✓1B--DYY-1 (x3)[^a^](#TF4){ref-type="table-fn"}FP, D, E5[^b^](#TF5){ref-type="table-fn"},4,4✓1Dn/d1En/d1FNGFI-AChIP5✓1Gn/d1Hn/d[^4][^5][^6]

*IS*PF analysis identifies two of the three known Yin Yang-1 (YY1) sites in promoter 1D, at position -4819 and -4603. The third known YY1 site (-4642 from ATG) was missed because of a discrepancy between the aligned genomic sequences and both the complete and core TRANSFAC matrices. The observed core was ATGGT rather than the expected ATGGC. Reducing the stringency of the TRANSFAC search correctly identifies this YY1 binding site, although with a much increased risk of false positive predictions (data not shown). Similarly, *IS*PF analysis of promoter 1F identifies the NGFI-A-binding site as being conserved between all species, after its initial identification in the homologous rat promoter 1~7~. *IS*PF analysis of the constituative promoter 1B, successfully predicts the three known SP1 sites ([@B31]).

Epigenetic sequence coverage
----------------------------

We previously showed that exons 1B--1H are differentially expressed in immune cells ([@B22]). Most of the five promoter regions were successfully bisulphite-sequenced in PBMCs. Multiple amplifications (nine nested and one simple reaction, [Figure 1](#F1){ref-type="fig"}) were required to cover 78% of the relevant promoters (1274 nucleotides) representing 40% of the total CpG island of 3.2 kbp. Figure 1Schematic representation of the Glucocorticoid receptor CpG island internal structure, the bisulphite sequencing strategy and primer locations. Known TFBS are shown as arrows and numbered from the ATG translation start codon in exon 2. **§** from ([@B32]), **†** from ([@B53]), **‡** homologous to the known rat site ([@B25],[@B27]), **¶** the ephemeric exon 1G has only been detected in the rat as its homologue 1~8~.

For some promoters it was not possible to get a complete sequence because of difficulties in amplifying long stretches of identical nucleotides after bisulphite modification. However, all conserved TFBS within the promoters of interest except YY1 (-4814, 1D) were completely sequenced.

Promoter 1D
-----------

YY1-binding sites at -4814/9 and -4603/8 include dinucleotides CpG^1^, CpG^16^ and CpG^17^ ([Figure 2](#F2){ref-type="fig"}). The CpG dinucleotide in the core binding site (ggCGccatctt) is known to be functionally sensitive to cytosine methylation ([@B33]). Among 26 donors none were methylated in CpG^1^, while two and one donor, respectively had \<25% methylation at CpG^16^ or CpG^17^. Similarly, *IS*PF analysis predicts within promoter 1D, 90--94 bp before the transcription start site a core TTCCG matrix (from either ELK-1 or c-Ets-1, both sharing the same core matrix). The predicted complete binding site for these two factors covers three CpG di-nucleotides (CpG^18-20^, [Figure 2](#F2){ref-type="fig"}). CpG^19^ forms part of the core matrix of ELK-1 and c-Ets-1. Between 25% and 50% methylation of CpG^18-20^ was observed in 4, 15 and 4 donors, respectively. Figure 2.*In silico* phylogenetic footprinting and bisulphite sequencing of promoter 1D. (**A**) *In silico* phylogenetic footprinting covers the start of the CpG island 340 nucleotides upstream of exon 1D through to exon 1D. (**B**) Percentage methylation was measured by direct electropherogram reading after bisulphite sequencing of 26 donors, covering CpG 6--27. Methylation levels are expressed by colour, levels from the scale at the panel top. (**C**) CpG identifiers and the unsequenced region of promoter 1D (grey background). (**D**) All TRANSFAC predicted human TFBS in promoter 1D are significant *IS*PF predictions.

Promoters 1J and 1E
-------------------

Bisulphite sequences of 269 bp covering the complete promoter 1E, exon 1J and part of promoter 1J were obtained ([Figure 1](#F1){ref-type="fig"}). Of the 28 potential CpG methylation sites, 12 were successfully sequenced: four in promoter 1J, four in exon 1J, and four in the promoter region immediately upstream of exon 1E ([Figure 3](#F3){ref-type="fig"}). Each of these sites (except CpG^27^) was methylated in one to three of the 26 donors. Interestingly, the *in silico* analysis identified nine TFBS that are evolutionarily highly conserved and present in at least four of the five species. However, only two of these nine sites contain CpG di-nucleotides: Pax3 (-4067) in promoter 1J (CpG^16^), and Sp3 (-4012) in promoter 1E (CpG^19^). Bisulphite sequencing of these nucleotides showed that whilst methylation was possible it was nevertheless rare (one and three donors, respectively at levels below 50%). Figure 3.*In silico* phylogenetic footprinting and bisulphite sequencing of promoters 1J and 1E. (**A**) *In silico* phylogenetic footprinting covers the end of exon 1D through promoter 1J, exon 1J, to exon 1E. (**B**) Percentage methylation was measured by direct electropherogram reading after bisulphite sequencing of 26 donors, covering CpG 16--27. Methylation levels are expressed by colour, levels from the scale at the panel top. (**C**) CpG identifiers and the unsequenced region of promoter 1J (grey background). Exon 1J is underlined. (**D**) TRANSFAC prediction for promoter 1J and E. Significant *IS*PF predictions are numbered corresponding to (**A**). Predictions in bold are high-quality *IS*PF predictions containing CpG dinucleotides.

The bisulphite sequenced region included exon 1J, and the first 24 nucleotides of exon 1E. Exon 1J contains four CpG dinucleotides (CpG[@B20; @B21; @B22; @B23], [Figure 3](#F3){ref-type="fig"}), whilst exon 1E contains only one (CpG^28^). Within these five exonic CpG dinucleotides, the methylation levels were similar to those in the neighbouring positions.

The methylation of CpG^27^ (six donors, \>25% methylation) was much greater than of the other positions within promoter 1E, and this position is the closest to the exon 1E TSS. TRANSFAC analysis of this position identifies an NGFI-A-binding site in the human sequence, but this is not an evolutionarily conserved position beyond human and chimpanzee. However, both the rat and mouse share a CACCCCCTCC sequence, differing by only a single nucleotide from the known active KROX response element (ctccccctc) ([@B34]). Thus the NGFI-A response element may be more conserved than predicted by *IS*PF.

Promoter 1F
-----------

*IS*PF predicted for promoter 1F several high quality potential TFBS, including the NGFI-A-binding site reported before ([@B25],[@B35]). Since methylation of the corresponding NGFI-A-binding site has been well documented in the rat, we tried to quantify the level of methylation by cloning. The F~CII~ PCR products were cloned and 10--12 colonies sequenced. The human NGFI-A core recognition motif, 5′-GCGGGGGCG-3′, includes two CpG sites (CpG[@B41; @B42], [Figure 4](#F4){ref-type="fig"}). Both of these positions were unmethylated in the majority of donors. In only 4 of the 26 donors less than 10% of the colonies screened were methylated at CpG^41^ (5′-end of the NGFI-A site). A similar level of methylation of CpG^42^ was found for only two donors ([Figure 4](#F4){ref-type="fig"}). These results show that methylation of the NGFI-A site is possible in the human, but is neither uniform nor frequent. The level of methylation observed by cloning was in agreement with the low but detectable levels seen in the sequencing electropherogram.

The sequence covering CpG[@B31; @B32; @B33] should be interpreted with caution as this region corresponds to the primer binding site of the F~CII~ forward primer. However, this region covers only one predicted human TFBS, HES1, with an *IS*PF value of only 2. Of all the promoters investigated, 1F contains the highest number of confident *IS*PF predictions (10 with *IS*PF \> 4), and has the highest percentage (60%) of methylatable CpG dinucleotides. Of the 42 CpG dinucleotides in promoter 1F, *IS*PF predictions cover only CpG[@B14; @B15] and CpG[@B41; @B42]. There was no visible methylation, however, for any of the 26 donors at either positions CpG^14^ or CpG^15^. Figure 4.*In silico* phylogenetic footprinting and bisulphite sequencing of promoter 1F. (**A**) *In silico* phylogenetic footprinting covers the end of exon 1B through to exon 1F. (**B**) Percentage methylation was measured by direct electropherogram reading (CpG[@B1; @B2; @B3; @B4; @B5; @B6; @B7; @B8; @B9; @B10; @B11; @B12; @B13; @B14; @B15; @B16; @B17; @B18; @B19; @B20; @B21; @B22; @B23; @B24; @B25; @B26; @B27; @B28; @B29; @B30]), or sequencing of 10--12 clones per donor (CpG[@B31; @B32; @B33; @B34; @B35; @B36; @B37; @B38; @B39; @B40; @B41; @B42; @B43]) after bisulphite sequencing of 26 donors, covering CpG 1--42. Methylation levels are expressed by colour, levels from the scale at the panel top. Blank squares indicate positions for which no data was obtainable. (**C**) CpG identifiers within the sequence of promoter 1F. (**D**) TRANSFAC prediction for promoter 1F. Significant *IS*PF predictions are numbered corresponding to (A). Predictions in bold are high-quality *IS*PF predictions containing CpG dinucleotides.

Promoter 1H
-----------

Promoter 1H, in contrast to the others, showed considerable methylation in up to 20 or 21 of the 26 donors (CpG^41^ and CpG^55^ respectively, [Figure 5](#F5){ref-type="fig"}). Methylation levels of individual donors were also much higher than in other *GR* promoters, with up to 75% methylation of CpG^41^ in two individuals. *IS*PF predicts that the region around CpG[@B14; @B15; @B16; @B17; @B18] is evolutionarily the most conserved. Half of the high-quality *IS*PF predictions (*IS*PF \> 4) contained CpG dinucleotides. However, methylation of these positions was limited to CpG^14^ and CpG^15^ (9 and 16 donors, respectively, all \<50%), whilst CpG^16,17^ ^and^ ^18^ were methylated in 2, 0 and 3 donors, respectively (all \<25%). Figure 5.*In silico* phylogenetic footprinting and bisulphite sequencing of promoter 1H. (**A**) *In silico* phylogenetic footprinting covers promoter 1H and part of exon 1H. (**B**) Percentage methylation was measured by direct electropherogram reading after bisulphite sequencing of 26 donors, covering CpG 1--42. Methylation levels are expressed by colour, levels from the scale at the panel top. Blank squares indicate positions for which no data was obtainable. (**C**) CpG identifiers within the sequence of promoter 1H and the unsequenced region (grey background). (**D**) TRANSFAC prediction for promoter 1H. Significant *IS*PF predictions are numbered corresponding to (A). Predictions in bold are high-quality *IS*PF predictions containing CpG dinucleotides.

DISCUSSION
==========

The results of this study show that the human *GR* promoter region is extensively methylated, and that levels and positions of methylation are highly diverse in normal donors. Although all of the alternative *GR* promoters investigated here are in a CpG island, most of the conserved TFBS contained methylatable CpG sites, suggesting that epigenetic mechanisms operate throughout the CpG island of this gene. This is the first report of such a comprehensive investigation of a complex CpG island containing multiple alternative first exons each with its own promoter and TSS.

Sequence patterns predicted unrealistically large numbers of TFBS throughout the human *GR* CpG island. By identifying evolutionarily conserved regions through interspecies sequence comparison ('phylogenetic footprinting') ([@B36]), and combining it with TRANSFAC TFBS predictions, a technique we term *in silico* phylogenetic footprinting, the number of putative TFBS was reduced by 3- to 4-fold. The successful prediction of the known TFBS within the CpG island ([@B27]) validated our approach, at least for the *GR*. It also suggests that mechanisms of transcription of the alternative 5′ mRNA transcript variants of *GR* are conserved in mammalian species.

In PBMCs, five of the seven CpG island promoters are known to be used ([@B22]). In these five promoters, covering more than 40% of the 3.2 kbp total *GR* CpG island over 70% of all CpG dinucleotides were methylated. Methylation of the *GR* first exon promoters occured throughout the CpG island and affected every promoter. Within our 26 donors, methylation was variable, but the majority of positions were methylated at levels above 25% in at least one donor. Not a single position was methylated in all donors.

Previously, methylation of only a 100 bp section of promoter 1F ([@B37]), and 331 bp of the constitutively active promoter 1C ([@B38]) have been investigated in humans. In agreement with our results, Lillycrop *et al*. observed variable methylation in both the human promoter 1C in cord blood and its homologue 1~10~ in the rat liver ([@B38],[@B39]), but no methylation levels of individual CpG dinucleotides were reported. In human hippocampi of both healthy and depressed individuals methylation of 1F CpG[@B35; @B36; @B37; @B38; @B39; @B40; @B41; @B42; @B43] was limited to \<10% methylation of CpG^35^ in 1 of 32 donors, similar to our findings in PBMCs ([@B37]). In the same study, CpG^43^ was almost 100% methylated in all donors with no methylation in any other site, which is in contrast to our findings in PBMCs where CpG^43^ was almost universally unmethylated. Thus, it is not clear to what extent positions and variability can be extrapolated from PBMCs to the human brain.

This variability in methylation patterns is in stark contrast to the promoter hypo- and hyper-methylation of large regions, and levels that are either undetectable, or nearly 100% in tumours. Because of their consistency CpG island hypermethylation profiles ('hypermethylomes') are now recognised as tumor-specific markers, similar to genetic and cytogenetic markers ([@B40; @B41; @B42]), for instance in prostate cancer ([@B43]), and in clear cell renal carcinomas ([@B44]).

The variability in methylation between donors and positions may reflect an important epigenetic mechanism suggested by studies both in animals and humans. Weaver was able to manipulate the methylation patterns by perinatal interventions. In the rat brain, methylation of the Ngfi-A-binding site in promoter 1~7~ was virtually complete in animals that had received poor postnatal maternal care, whilst those receiving better maternal care were virtually unmethylated ([@B25],[@B26],[@B45]). By cross fostering pups between dams providing good or poor post-natal care the pups developed the epigenome of the foster mother. Similarly, methylation of promoter 1~10~ was reduced in pups born to dams fed on a protein-restricted diet during pregnancy ([@B38],[@B39]). These rat experiments suggest that *Gr* expression and perhaps sensitivity can be fine-tuned as the host adapts to its environment during early life. Recent human data from the *GR* support the above rat data ([@B46]). Although in the latter study methylation levels observed were very low, methylation of exon 1F in fetal cord blood was sensitive to maternal mood. Thus the heterogeneity of methylation patterns observed in all the CpG island dinucleotides and in particular the different alternative *GR* promoters reflect a mechanism of epigenetic programming of GR fine tuning programmed by differences in early life environment and events. Methylation of these important evolutionarily conserved TFBS containing methylatable CpG dinucleotides would suggest that such methylation will have considerable effects on the transcription from the TSS immediately downstream. In both these cases, the methylation of single CpG dinucleotides within the promoter that has been implicated. Therefore, the observed variability both in levels and positions of methylation may reflect some specificity. Methylation of different TFBS within a promoter will modulate the promoter response, in a tightly controlled individualised fashion. Data from other genes support the role of the inter-uterine environment in lasting epigenetic conditioning. In a rodent type 2 diabetes model, Park *et al*. ([@B47]) showed that retarded interuterine growth resulted in lower *Pdx1* levels, a key correlate of adult β cell function. As for the *GR*, the *Pdx1* promoter is in a CpG island. Methylation of the 14 CpG pairs in the 275 bp promoter region was shown to be responsible for the reduced *Pdx1* levels. Since methylation modulates promoter activity the highly individual methylation patterns of *GR* promoters strongly suggest highly individualised fine tuning of *GR* expression. However, many other factors such as age ([@B7]) and drug intake ([@B48; @B49; @B50]) may influence and add to this variability.

CpG methylation has also been implicated in tissue-specific regulation. GNAL ([@B51]) and PNP22 ([@B52]) are such examples, but both genes have a simpler structure with alternative first exons and promoters in independent CpG islands. The tissue-specific expression of Toll-like receptor 2 (TLR2) is, however, the result of strong methylation of the 20 CpG pairs in the ∼220 bp proximal promoter in the upstream CpG island. This promoter is very similar in size and number of CpG pairs as each of the individual *GR* promoters investigated here. Although ubiquitously expressed, in most tissues functional levels of GR are tightly and individually regulated in all tissues. We have previously observed that the multiple alternative *GR* first exons are expressed in a tissue-specific manner each using its own promoter ([@B22],[@B27]). Since the complete *GR* CpG island with all the promoters can be methylated we further propose that CpG methylation orchestrates alternative first exon usage and silencing.

Currently an incredible transcriptional variability, especially in the 5′ region unfolds. Already in 2006 the number of genes with multiple alternative first exons has passed 7600 ([@B21]), and at least 43 genes have more than 10 first exons. Many of these genes are expressed in a tissue-specific manner. With 78% of the evolutionarily conserved alternative first exons falling into CpG islands epigenetic modulation and tissue-specific expression through methylation of individual promoters within CpG islands is bound to be a biologically important and widely used mechanism throughout many phyla.
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[^1]: ^a^Fwd, forward or sense primer; Rev, reverse or antisense primer. Degenerate nucleotides following IUPAC codes.

[^2]: ^b^Locations given with respect to the ATG start codon.

[^3]: ^c^*T*~m~, annealing temperature in PCR.

[^4]: n/d: Not experimentally determined.

[^5]: ^a^YY-1-binding site initially identified as part of promoter 1B, subsequent identification of alternate first exons would suggest that it is part of promoter 1D.

[^6]: ^b^This YY-1-binding site is outside the CpG island and not considered further.
